Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public Citizen Seeks To Hold Up Lilly Prasugrel Review For Further Data

Executive Summary

Public Citizen's decision to file a citizen petition June 3 asking FDA to halt its review of Lilly/Daiichi Sankyo's prasugrel suggests the watchdog group may believe the agency is on the verge of approving the platelet inhibitor

You may also be interested in...



Does TRITON Really Show If Effient Was Better Than Plavix?

The pivotal TRITON-TIMI 38 trial supporting the approval of Lilly/Daiichi Sankyo's Effient (prasugrel) was a lot of things that FDA likes: big (nearly 14,000 patients), long (a median 14.5 months of treatment) and clearly focused on clinical outcomes (the primary endpoint was a composite of cardiovascular death, non-fatal MI, and non-fatal stroke)

Does TRITON Really Show If Effient Was Better Than Plavix?

The pivotal TRITON-TIMI 38 trial supporting the approval of Lilly/Daiichi Sankyo's Effient (prasugrel) was a lot of things that FDA likes: big (nearly 14,000 patients), long (a median 14.5 months of treatment) and clearly focused on clinical outcomes (the primary endpoint was a composite of cardiovascular death, non-fatal MI, and non-fatal stroke)

Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role

FDA's appointment of a high-profile consumer advocate to an Office of the Commissioner post continues a strategy of bringing some of the most outspoken critics of both the drug industry and its regulatory agency into FDA

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel